In breast cancer, fatostatin prevents SREBP2 activation, attenuating osteoclastogenesis and breast cancer-induced osteolysis in vivo, thereby providing therapeutic benefits for patients with osteolytic bone lesions (Jie et al., 2019). This evidence concerns the gene SREBF2 and breast cancer.